BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors

TIPRANKS00:32

Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604599028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604599028","market":"nz","top_or_hot":-1,"title":"BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors","media":"TIPRANKS","content":"<div>\n<p>Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/bds-bd-prevue-ii-study-wraps-up-what-a-post‑market-win-could-mean-for-bdx-investors?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-17 00:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/company-announcements/bds-bd-prevue-ii-study-wraps-up-what-a-post‑market-win-could-mean-for-bdx-investors?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/bds-bd-prevue-ii-study-wraps-up-what-a-post‑market-win-could-mean-for-bdx-investors?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854103824.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","start_time":0,"source_url":"https://www.tipranks.com/news/company-announcements/bds-bd-prevue-ii-study-wraps-up-what-a-post‑market-win-could-mean-for-bdx-investors?utm_source=itigerup.com&utm_medium=referral","article_id":"2604599028","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bds-bd-prevue-ii-study-wraps-up-what-a-post‑market-win-could-mean-for-bdx-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604599028","pubTimestamp":1768581120,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4585":"ETF&股票定投概念","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4082":"医疗保健设备","BK4212":"包装食品与肉类","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","BK4504":"桥水持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","POST":"Post Holdings","BK4588":"碎股","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BDX":"碧迪医疗","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","BK4211":"区域性银行","ISBC":"投资者银行","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC"},"translate_title":"BD的BD Prevue II研究总结：上市后的胜利对BDX投资者意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1.5,"ISBC":1.5,"POST":1.5},"content_text":"Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604599028","isCrawlerRequest":true}